The US Food and Drug Administration granted clearances for various tests for infectious diseases, coagulation disorders, and drug susceptibility.

NEW YORK – Adaptive Biotechnologies on Thursday reported a 22 percent increase in Q3 revenues driven by an increase in minimal residual disease testing.

The firm had received notice last year that it was out of compliance with a requirement to maintain a minimum $15 million market value of publicly held shares.

The firm said on Wednesday that it has been hiring key sales and marketing personnel as it prepares to ramp up sales in 2025 of its PreTRM proteomic test.

NEW YORK – Adaptive Biotechnologies announced on Thursday that its blood-based ClonoSeq assay has received expanded coverage from Medicare administrative contractor Palmetto GBA for the detection and ...

The firm reported that its adjusted diagnostics revenues rose less than 1 percent, excluding the COVID-19 rapid antigen testing business that the firm exited last year.

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

SensID manufactures reference materials and quality controls for molecular diagnostics with a focus on oncology and precision medicine.

Fadel Alshalabi, owner and CEO of Crestar Labs, and Samuel Harris, owner of Flojo Recruiting, conspired to bill Medicare and Medicaid for millions of dollars in genetic test orders.

NEW YORK – MDxHealth on Wednesday reported that its third quarter revenues rose 21 percent to $23.3 million from $19.4 million in Q3 2023. When adjusted for a one-time backlog of Select MDx revenue in ...

Revenues for BD's Life Sciences segment, which includes the Integrated Diagnostic Solutions and Biosciences business units, were up 1 percent to $1.34 billion. The firm's blood-based ClonoSeq test can ...

The company reported on Tuesday that its revenues jumped 8 percent in North America and Europe during the third quarter but fell slightly in the rest of the world.